Standard BioTools (LAB) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed Standard BioTools (LAB) over the past year, losing 11.1% versus a loss of 47.8%. Over five years, TLSI leads with a -57.1% price change compared with -87.3% for LAB. Standard BioTools is the larger company by market cap ($255.1 million vs $254.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LAB | TLSI |
|---|---|---|
| Share price | $0.6499 | $4.13 |
| Market cap | $255.14M | $254.12M |
| 1-day change | -4.24% | -2.89% |
| YTD return | -46.98% | -39.11% |
| 1-year return | -47.79% | -11.09% |
| 5-year return | -87.29% | -57.07% |
| EPS (TTM) | $-0.13 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.72 | $7.95 |
| 52-week low | $0.63 | $2.20 |
| Distance from 52-week high | -62.22% | -48.09% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +107.72% | +152.00% |
| Average volume | 1.57M | 276.43K |
| Shares outstanding | 392.58M | 61.57M |
| Employees | 385 | 102 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSI has outperformed LAB by 36.7 percentage points over the past year.
- The two companies sit in different sectors: Standard BioTools in Industrials and TriSalus Life Sciences in Health Care.
About Standard BioTools
LAB stock →Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
LAB vs TLSI FAQ
Which is bigger, Standard BioTools or TriSalus Life Sciences?
Standard BioTools (LAB) is larger, with a market capitalization of $255.14M compared with $254.12M for TriSalus Life Sciences (TLSI).
Which stock has performed better over the past year, LAB or TLSI?
TLSI returned -11.09% over the past 12 months, compared with -47.79% for LAB (price return, excluding dividends). Past performance does not predict future results.
Are Standard BioTools and TriSalus Life Sciences in the same industry?
No. Standard BioTools is in the Industrials sector, while TriSalus Life Sciences is in Health Care.